Healthy Opioid Prescription Engagement

Launched by JERRY COCHRAN · Nov 18, 2021

Keywords

ClinConnect Summary

The Healthy Opioid Prescription Engagement trial is studying a new approach to help people who may be misusing opioids, which are strong pain medications. This study is taking place in 14 community pharmacies and aims to see if a program called Brief Intervention-Medication Therapy Management (BI-MTM) can effectively prevent opioid misuse and improve patient health. If you or someone you know is an adult who speaks English and has shown signs of opioid misuse, you might be eligible to participate.

Participants in the study can expect to receive support and guidance on managing their opioid use in a safe way. It’s important to note that those who are pregnant, recently experienced severe mental health issues, or are currently undergoing cancer treatment won't be able to join the study. The research team will ensure you have reliable contact methods to stay in touch throughout the study. This trial is actively recruiting participants, and it represents a community-based effort to address the opioid crisis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult (≥18 years)
• • English speaking
• • Not receiving cancer treatment
• • Who have a positive opioid misuse screen on the POMI will be eligible to learn about this study
• Exclusion Criteria:
• • Are pregnant (given potential pre/post-natal opioid use complications among pregnant women/offspring
• • Can-not provide collateral contact information for ≥2 contact persons (to ensure consistent contact/follow up)
• • Do not have a reliable land line or mobile phone to be contacted by study staff
• • Are filling only buprenorphine (given some formulations are not indicated for pain)
• • Plan to leave the area for an extended period of time in the next 6 months
• • Have had a psychotic and/or manic episode in the last 30 days (before consent, patients will be asked to screen for psychosis
• • Do not provide permission to access their state prescription drug monitoring data.